Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fetal growth in gestational diabetes mellitus (GDM) is directly linked to maternal glycaemic control; however, this relationship may be altered by oral anti-hyperglycaemic agents. Unlike insulin, such drugs cross the placenta and may thus have independent effects on fetal or placental tissues. We investigated the association between GDM treatment and fetal, neonatal, and childhood growth. METHODS AND FINDINGS: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and Cochrane databases were systematically searched (inception to 12 February 2020). Outcomes of GDM-affected pregnancies randomised to treatment with metformin, glyburide, or insulin were included. Studies including preexisting diabetes or nondiabetic women were excluded. Two reviewers independently assessed eligibility and risk of bias, with conflicts resolved by a third reviewer. Maternal outcome measures were glycaemic control, weight gain, and treatment failure. Offspring anthropometric parameters included fetal, neonatal, and childhood weight and body composition data. Thirty-three studies (n = 4,944), from geographical locations including Europe, North Africa, the Middle East, Asia, Australia/New Zealand, and the United States/Latin America, met eligibility criteria. Twenty-two studies (n = 2,801) randomised women to metformin versus insulin, 8 studies (n = 1,722) to glyburide versus insulin, and 3 studies (n = 421) to metformin versus glyburide. Eleven studies (n = 2,204) reported maternal outcomes. No differences in fasting blood glucose (FBS), random blood glucose (RBS), or glycated haemoglobin (HbA1c) were reported. No studies reported fetal growth parameters. Thirty-three studies (n = 4,733) reported birth weight. Glyburide-exposed neonates were heavier at birth (58.20 g, 95% confidence interval [CI] 10.10-106.31, p = 0.02) with increased risk of macrosomia (odds ratio [OR] 1.38, 95% CI 1.01-1.89, p = 0.04) versus neonates of insulin-treated mothers. Metformin-exposed neonates were born lighter (-73.92 g, 95% CI -114.79 to -33.06 g, p < 0.001) with reduced risk of macrosomia (OR 0.60, 95% CI 0.45-0.79, p < 0.001) than insulin-exposed neonates. Metformin-exposed neonates were born lighter (-191.73 g, 95% CI -288.01 to -94.74, p < 0.001) with a nonsignificant reduction in macrosomia risk (OR 0.32, 95% CI 0.08-1.19, I2 = 0%, p = 0.09) versus glyburide-exposed neonates. Glyburide-exposed neonates had a nonsignificant increase in total fat mass (103.2 g, 95% CI -3.91 to 210.31, p = 0.06) and increased abdominal (0.90 cm, 95% CI 0.03-1.77, p = 0.04) and chest circumferences (0.80 cm, 95% CI 0.07-1.53, p = 0.03) versus insulin-exposed neonates. Metformin-exposed neonates had decreased ponderal index (-0.13 kg/m3, 95% CI -0.26 to -0.00, p = 0.04) and reduced head (-0.21, 95% CI -0.39 to -0.03, p = 0.03) and chest circumferences (-0.34 cm, 95% CI -0.62 to -0.05, p = 0.02) versus the insulin-treated group. Metformin-exposed neonates had decreased ponderal index (-0.09 kg/m3, 95% CI -0.17 to -0.01, p = 0.03) versus glyburide-exposed neonates. Study limitations include heterogeneity in dosing, heterogeneity in GDM diagnostic criteria, and few studies reporting longitudinal growth outcomes. CONCLUSIONS: Maternal randomisation to glyburide resulted in heavier neonates with a propensity to increased adiposity versus insulin- or metformin-exposed groups. Metformin-exposed neonates were lighter with reduced lean mass versus insulin- or glyburide-exposed groups, independent of maternal glycaemic control. Oral anti-hyperglycaemics cross the placenta, so effects on fetal anthropometry could result from direct actions on the fetus and/or placenta. We highlight a need for further studies examining the effects of intrauterine exposure to antidiabetic agents on longitudinal growth, and the importance of monitoring fetal growth and maternal glycaemic control when treating GDM. This review protocol was registered with PROSPERO (CRD42019134664/CRD42018117503).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In meta-analyses and systematic reviews, glyburide was associated with a higher rate of neonatal hypoglycemia, macrosomia, and increased neonatal abdominal circumference than insulin or metformin (78,79).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [79]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Elective induction versus spontaneous labor after sonographic diagnosis of fetal macrosomia.
Combs, C. A., Singh, N. B., & Khoury, J. C. (1993) · PubMed · Cited by 2,500
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Metformin reduces cellular energy production via inhibition of complex I of the mitochondrial electron transport chain, leading to an increase in both ADP/ATP and AMP/ATP ratios, inhibiting (mTOR) actions and down-regulating pathways associated with cell growth and proliferation [69,70].”
BackgroundMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 8×
“The majority of studies randomised women between 20 and 36 weeks of gestation [31,32,34,42,43,44,48,49,50,51,52,53,54,58], although others [36– 39,55] randomised women between 11 and 33 weeks of gestation.”
BackgroundMethodResultInfluentialA comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 4×
“Three studies [35,36,53], including 523 women, recorded total gestational weight gain in glyburide compared to insulin-treated women.”
BackgroundInfluentialGestational Diabetes Mellitus and Macrosomia: A Literature Review
KC, K., Shakya, S., & Zhang, H. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000371628 · Cited by 917
Damm, P., Houshmand-Oeregaard, A., Kelstrup, L., Lauenborg, J., Mathiesen, E. R., & Clausen, T. D. (2016) · Diabetologia · doi:10.1007/s00125-016-3985-5 · Cited by 620 · cited 1×
“, metabolic dysregulation in later childhood [9,10].”
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Howell, J. J., Hellberg, K., Turner, M., Talbott, G., Kolar, M. J., Ross, D. S., Hoxhaj, G., Saghatelian, A., Shaw, R. J., & Manning, B. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.009 · Cited by 408 · cited 1×
“One of metformin’s major intracellular effects is on the mammalian target of rapamycin (mTOR) pathway, known to be important for nutrient sensing, by both 5 AMP-activated protein kinase (AMPK)-dependent [66] and AMPK-independent [67] mechanisms.”
BackgroundMetformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379
Thompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Elective induction versus spontaneous labor after sonographic diagnosis of fetal macrosomia
Combs, C. A., Singh, N. B., & Khoury, J. C. (1994) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(94)90050-7 · Cited by 376
Practice Bulletin No. 180: gestational diabetes mellitus.
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002159 · Cited by 324
Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000456 · Cited by 305
Jansson, N., Rosario, F. J., Gaccioli, F., Lager, S., Jones, H. N., Roos, S., Jansson, T., & Powell, T. L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2667 · Cited by 305 · cited 1×
“It is possible that metformin-induced mTOR inhibition could restrict placental nutrient transfer, hence limiting transport of glucose and amino acids [68] and potentially providing a mechanism for lower birth weight and reduced ponderal index observed in metformin-exposed neonates compared to their insulin- or glyburi…”
Hebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252 · cited 1×
“The relationship between maternal and fetal glyburide levels is complicated by the drug’s high protein binding and active feto-maternal efflux [25,62].”
BackgroundTarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002848 · Cited by 251 · cited 7×
“Details for the database search strategies for metformin versus insulin comparisons can be found in [29].”
BackgroundMethodInfluentialSelf-citationPlacental passage of metformin in women with polycystic ovary syndrome
Vanky, E., Zahlsen, K., Spigset, O., & Carlsen, S. M. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.051 · Cited by 245
Ijäs, H., Vääräsmäki, M., Morin-Papunen, L., Keravuo, R., Ebeling, T., Saarela, T., & Raudaskoski, T. (2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02763.x · Cited by 215
Population pharmacokinetics of metformin in late pregnancy
Charles, B., Norris, R., Xiao, X., & Hague, W. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000184161.52573.0e · Cited by 212
Pharmacokinetics of metformin during pregnancy
Eyal, S., Easterling, T. R., Carr, D., Umans, J. G., Miodovnik, M., Hankins, G. D. V., Clark, S. M., Risler, L., Wang, J., Kelly, E. J., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031245 · Cited by 209
Maternal and neonatal outcomes of large for gestational age pregnancies
WEISSMANN‐BRENNER, A., SIMCHEN, M. J., ZILBERBERG, E., KALTER, A., WEISZ, B., ACHIRON, R., & DULITZKY, M. (2012) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2012.01412.x · Cited by 204
Niromanesh, S., Alavi, A., Sharbaf, F. R., Amjadi, N., Moosavi, S., & Akbari, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.031 · Cited by 203
The costs of diabetes treatment in low- and middle-income countries: a systematic review
Moucheraud, C., Lenz, C., Latkovic, M., & Wirtz, V. J. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2018-001258 · Cited by 198
The Prevalence of Gestational Diabetes
Melchior, H., Kurch-Bek, D., & Mund, M. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0412 · Cited by 185 · cited 2×
“Examining in detail the mechanisms by which the various pharmacological options for GDM treatment may impact the developing fetus and/or placenta in both the short and long term is particularly important, given the increasing incidence of GDM worldwide [1,2].”
BackgroundRandomized trial of metformin vs insulin in the management of gestational diabetes
Spaulonci, C. P., Bernardes, L. S., Trindade, T. C., Zugaib, M., & Francisco, R. P. V. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.022 · Cited by 183
Mitanchez, D. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.11.013 · Cited by 183
13. Management of Diabetes in Pregnancy
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s016 · Cited by 179
Metformin Compared With Glyburide in Gestational Diabetes: A Randomized Controlled Trial
Moore, L. E., Clokey, D., Rappaport, V. J., & Curet, L. B. (2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181c52132 · Cited by 177
Tertti, K., Ekblad, U., Koskinen, P., Vahlberg, T., & Rönnemaa, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12017 · Cited by 174
Perinatal outcomes and the use of oral hypoglycemic agents
Bertini, A. M., Silva, J. C., Taborda, W., Becker, F., Bebber, F. R. L., Viesi, J. M. Z., Aquim, G., & Ribeiro, T. E. (2005) · Journal of Perinatal Medicine · doi:10.1515/jpm.2005.092 · Cited by 161
Galván, C. A. G., Medellín Morales, A., Hg, T. S., Contreras, A. E. T., & Ovalle Berumen, F. (1981) · PubMed · Cited by 155
Management of Diabetes in Pregnancy
Ballas, J., Moore, T. R., & Ramos, G. A. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0249-0 · Cited by 149
Hyperglycemia in pregnancy: prevalence, impact, and management challenges
Farrar, D. (2016) · International Journal of Women's Health · doi:10.2147/ijwh.s102117 · Cited by 129
Ijäs, H., Vääräsmäki, M., Saarela, T., Keravuo, R., & Raudaskoski, T. (2015) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12964 · Cited by 127
Moore, L. E., Briery, C. M., Clokey, D., Martin, R. W., Williford, N. J., Bofill, J. A., & Morrison, J. C. (2007) · PubMed · Cited by 123
Metformin compared with glyburide for the management of gestational diabetes
Silva, J. C., Pacheco, C., Bizato, J., de Souza, B. V., Ribeiro, T. E., & Bertini, A. M. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.04.028 · Cited by 115 · cited 3×
“In three studies [38,39,55] including 421 participants, metformin-exposed neonates were lighter by an average of 191.”
BackgroundResultSénat, M.-V., Affres, H., Letourneau, A., Coustols-Valat, M., Cazaubiel, M., Legardeur, H., Jacquier, J. F., Bourcigaux, N., Simon, E., Rod, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.4072 · Cited by 114
Silva, J. C., Fachin, D. R. R. N., Coral, M. L., & Bertini, A. M. (2012) · jpme · doi:10.1515/jpm-2011-0175 · Cited by 109
Insulin Glargine Safety in Pregnancy
Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G. (2010) · Diabetes Care · doi:10.2337/dc09-1045 · Cited by 104
Lain, K. Y., Garabedian, M. J., Daftary, A., & Jeyabalan, A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.02.038 · Cited by 100 · cited 8×
“Three studies [35,36,53], including 523 women, recorded total gestational weight gain in glyburide compared to insulin-treated women.”
BackgroundMethodResultInfluentialSMFM statement: pharmacological treatment of gestational diabetes
(2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.041 · Cited by 94
Glyburide transport across the human placenta
Schwartz, R. A., Rosenn, B., Aleksa, K., & Koren, G. (2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000672 · Cited by 83 · cited 1×
“The relationship between maternal and fetal glyburide levels is complicated by the drug’s high protein binding and active feto-maternal efflux [25,62].”
BackgroundTHE EFFECTS OF INSULIN ON THE GROWTH RATE OF THE SHEEP FETUS DURING LATE GESTATION
Fowden, A. L., Hughes, P., & Comline, R. S. (1989) · Quarterly Journal of Experimental Physiology · doi:10.1113/expphysiol.1989.sp003322 · Cited by 83
Ashoush, S., El‐Said, M., Fathi, H., & Abdelnaby, M. (2016) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.12950 · Cited by 80
Lee, N., Hébert, M. F., Prasad, B., Easterling, T. R., Kelly, E. J., Unadkat, J. D., & Wang, J. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054072 · Cited by 73
Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety
Nicholson, W., & Baptiste-Roberts, K. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.018 · Cited by 72
Glyburide as treatment option for gestational diabetes mellitus
Tempe, A., & Mayanglambam, R. D. (2013) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.12042 · Cited by 71
Sridhar, S. B., Ferrara, A., Ehrlich, S. F., Brown, S. D., & Hedderson, M. M. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318291b15c · Cited by 66
Effects of Insulin and Glucose Concentrations on Glucose Utilization in Fetal Sheep
Hay, W. W., Meznarich, H. K., DiGiacomo, J. E., Hirst, K., & Zerbe, G. O. (1988) · Pediatric Research · doi:10.1203/00006450-198804000-00008 · Cited by 63
Could Metformin Manage Gestational Diabetes Mellitus instead of Insulin?
Saleh, H. S., Abdelsalam, W. A., Mowafy, H. E., & Abd ElHameid, A. A. (2016) · International Journal of Reproductive Medicine · doi:10.1155/2016/3480629 · Cited by 61
Organic Cation Transporter 3 Facilitates Fetal Exposure to Metformin during Pregnancy
Lee, N., Hébert, M. F., Wagner, D. J., Easterling, T. R., Liang, C. J., Rice, K. M., & Wang, J. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112482 · Cited by 60
Mukhopadhyay, P., Bag, T. S., Kyal, A., Saha, D. P., & Khalid, N. (2012) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-1167 · Cited by 56
Rodó, C., Arévalo, S., Lewi, L., Couck, I., Hollwitz, B., Hecher, K., & Carreras, E. (2017) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-017-1435-0 · Cited by 51
Insulin Detemir Does Not Cross the Human Placenta
Suffecool, K., Rosenn, B., Niederkofler, E. E., Kiernan, U. A., Foroutan, J., Antwi, K., Ribar, A., Bapat, P., & Koren, G. (2015) · Diabetes Care · doi:10.2337/dc14-2090 · Cited by 45
Glibenclamida no tratamento do diabete melito gestacional em estudo comparado à insulina
Silva, J. C., Bertini, A. M., Taborda, W., Becker, F., Bebber, F. R. L., Aquim, G. M. D. C., & Viesi, J. M. Z. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000400007 · Cited by 42
Metformin prevents macrosomia and neonatal morbidity in gestational diabetes
Hasan, J. A., Karim, N., & Sheikh, Z. (2012) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.283.1686 · Cited by 39
Gestational diabetes mellitus--negotiating the confusion.
Nankervis, A. J., & CONN, J. J. (2013) · PubMed · Cited by 37
Feto-maternal outcomes and Glycemic control in Metforminversus insulin treated Gestational Diabetics
Arshad, R., Khanam, S., SHAIKH, D. F., & Karim, D. N. (2017) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.335.13286 · Cited by 37
Tertti, K., Toppari, J., Virtanen, H. E., Sadov, S., & Rönnemaa, T. (2016) · The Review of Diabetic Studies · doi:10.1900/rds.2016.13.59 · Cited by 36
Neonatal outcomes of macrosomic infants of diabetic and non-diabetic mothers
Cordero, L., Paetow, P., Landon, M. B., & Nankervis, C. A. (2015) · Journal of Neonatal-Perinatal Medicine · doi:10.3233/npm-15814102 · Cited by 35
Mirzamoradi, M., Heidar, Z., Faalpoor, Z., Naeiji, Z., & Jamali, R. (2015) · PubMed · Cited by 35
Tertti, K., Laine, K., Ekblad, U., Rinne, V. M., & Rönnemaa, T. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0570-6 · Cited by 35
Figueroa, H. M., Schuster, M., Maggio, L., Pedroza, C., Chauhan, S. P., & Paglia, M. J. (2017) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002101 · Cited by 30
Cho, H. Y., Jung, I., & Kim, S. J. (2016) · Medicine · doi:10.1097/md.0000000000004712 · Cited by 23
Reynolds, R. M., Denison, F. C., Juszczak, E., Bell, J. L., Penneycard, J. M., Strachan, M. W. J., Lindsay, R. S., Alexander, C. I., Love, C. D. B., Whyte, S., et al. (2017) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-017-1505-3 · Cited by 22
Is Glyburide Safe in Pregnancy?
Kimber-Trojnar, Ż., Marciniak, B., Patro-Małysza, J., Skórzyńska-Dziduszko, K., Poniedziałek‐Czajkowska, E., Mierzyński, R., Gałczyński, K., Trojnar, M. P., Leszczyńska‐Gorzelak, B., & Oleszczuk, J. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140330200254 · Cited by 20
Oral hypoglycemic therapy: Understanding the mechanisms of transplacental transfer
Pollex, E. K., Feig, D. S., & Koren, G. (2010) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767050903550881 · Cited by 16
Lain, K. Y., Garabedian, M. J., Daftary, A. R., & Jeyabalan, A. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.09.103 · Cited by 11
TREATMENT OF GESTATIONAL DIABETES MELLITUS: INSULIN OR METFORMIN?
Somani, P. S., Sahana, P. K., Chaudhuri, P., & Sengupta, N. (2016) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2016/1011 · Cited by 10
Metformin Opposed to Insulin in the Management of Gestational Diabetes
Borg, H. M., & Ezat, S. (2016) · Cited by 9
Comparison of Metformin with Insulin in the Management of Gestational Diabetes
Bukhari, S. M., Awan, M., & Ayoub, I. (2019) · Journal of Medicine, Physiology and Biophysics · doi:10.7176/jmpb/54-11 · Cited by 9
Foetal Programming in a Diabetic Pregnancy: Long-Term Implications for the Offspring
Krishnaveni, G. V., & Yajnik, C. S. (2017) · Current Science · doi:10.18520/cs/v113/i07/1321-1326 · Cited by 5
Rowan, J. A., Rush, E. C., Plank Lindsay, D., Lu, J., Obolonkin, V., Coat, S., Hague, W. M., 张贝, & 巩纯秀 (2018) · doi:10.3760/cma.j.issn.1007-9742.2018.09.120 · Cited by 2
Research works printed but not linked: 1
- International Diabetes Federation. IDF diabetes atlas. 8th edition Brussels: International Diabetes Federation; 2017.
Cited by
Gestational diabetes mellitus - A metabolic and reproductive disorder
Choudhury, A. A., & Devi Rajeswari, V. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112183 · Cited by 442
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
GDF15 linked to maternal risk of nausea and vomiting during pregnancy
Fejzo, M., Rocha, N., Cimino, I., Lockhart, S. M., Petry, C. J., Kay, R. G., Burling, K., Barker, P., George, A. L., Yasara, N., et al. (2024) · Nature · doi:10.1038/s41586-023-06921-9 · Cited by 204
Metadata
- Authors
- Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E.
- Affiliations
- University of Cambridge (GB)
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-05-22
- Volume
- 17
- Issue
- 5
- Pages
- e1003126
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC7244100
- OpenAlex
- W3027421343
- Cited by
- 73
- References
- 78
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 11 · 2023: 18 · 2022: 12 · 2021: 15 · 2020: 2
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- British Heart Foundation (RG/17/12/33167)
- Medical Research Council (MC_ UU_12012/4)
- Isaac Newton Trust/Wellcome Trust ISSF/ University of Cambridge Joint Research Grant
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Keywords
- gestational diabetes mellitus, metformin, glibenclamide, insulin therapy, neonatal anthropometry, birth weight, macrosomia, fetal growth, child growth, maternal glycaemic control, placental transfer
- MeSH terms
- Anthropometry, Birth Weight, Blood Glucose, Female, Fetal Macrosomia, Glyburide, Humans, Hypoglycemic Agents, Infant, Newborn, Pregnancy, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.